How Gilead Intends To Deliver On Promise Of Remdesivir For COVID-19
Executive Summary
When the coronavirus hit China, Gilead only had enough remdesivir for 5,000 patients. Here’s how it went about expanding production.
You may also be interested in...
A Pandemic Template For Swift Approval? Veklury Stability Questions Deferred For Later Study
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.
US COVID Antibody Drug Supply: Regeneron, Lilly, AstraZeneca To Contribute To 1M Dose Goal For 2020
Precise amounts to be supplied by each company will depend in part on whether the monoclonal antibody drugs are used for prevention or treatment because dosage strengths will be different.
HHS Shifts Remdesivir Distribution To Gilead As Supply Crunch Eases
AmerisourceBergen will continue to serve as the sole US distributor of Veklury (remdesivir) through the end of this year and will continue to sell the the COVID-19 treatment directly to hospitals.